The liver X‐receptor alpha controls hepatic expression of the human bile acid–glucuronidating UGT1A3 enzyme in human cells and transgenic mice

Mélanie Verreault, Kathy Senekeo‐Effenberger, Jocelyn Trottier, Jessica A. Bonzo, Julie Bélanger, Jenny Kaeding, Bart Staels, Patrick Caron, Robert H. Tukey, Olivier Barbier – 26 July 2006 – Glucuronidation, an important bile acid detoxification pathway, is catalyzed by enzymes belonging to the UDP‐glucuronosyltransferase (UGT) family. Among UGT enzymes, UGT1A3 is considered the major human enzyme for the hepatic C24‐glucuronidation of the primary chenodeoxycholic (CDCA) and secondary lithocholic (LCA) bile acids.

Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection

Atsushi Ozasa, Yasuhito Tanaka, Etsuro Orito, Masaya Sugiyama, Jong‐Hon Kang, Shuhei Hige, Tomoyuki Kuramitsu, Kazuyuki Suzuki, Eiji Tanaka, Shunichi Okada, Hajime Tokita, Yasuhiro Asahina, Kazuaki Inoue, Shinichi Kakumu, Takeshi Okanoue, Yoshikazu Murawaki, Keisuke Hino, Morikazu Onji, Hiroshi Yatsuhashi, Hiroshi Sakugawa, Yuzo Miyakawa, Ryuzo Ueda, Masashi Mizokami – 26 July 2006 – The outcome of acute hepatitis B virus (HBV) infection is variable, influenced by host and viral factors.

Pulmonary hypertension after liver transplantation in patients with antecedent hepatopulmonary syndrome: A report of 2 cases and review of the literature

Federico Aucejo, Charles Miller, David Vogt, Bijan Eghtesad, Shunichi Nakagawa, James K. Stoller – 25 July 2006 – Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PPHTN) are distinct clinical entities that may complicate liver disease. Although HPS and PPHTN are different, several reports describe 6 patients in whom both conditions have occurred, either concurrently or sequentially, sometimes with the onset of PPHTN after liver transplantation.

Treating hepatitis C infection in liver transplant recipients

Norah A. Terrault, Marina Berenguer – 25 July 2006 – Chronic infection with hepatitis C virus (HCV) is a growing problem worldwide, with up to 300 million individuals infected, and those with chronic infection are at risk for cirrhosis and hepatocellular carcinoma. HCV infection is the most common indication for liver transplantation in the United States and Europe. Unfortunately, although transplantation is effective for treating decompensated cirrhosis and limited hepatocellular carcinoma associated with hepatitis C, HCV reinfection is virtually the rule among transplant recipients.

Subscribe to